Agilent Technologies ClearSeq Comprehensive Cancer research panel

Agilent Technologies has launched the ClearSeq Comprehensive Cancer research panel, designed to improve the speed and accuracy of clinical cancer research. The product will enable researchers to rapidly and accurately identify disease-associated variants in tumour samples - information that can be vital to research in cancer treatments.

The off-the-shelf cancer research panel provides an accelerated solution for the analysis of many oncogenes and tumour suppressors. The panel is the latest addition to Agilent’s growing portfolio of ClearSeq cancer research panels and targets 151 key oncology genes containing disease-associated variants. Designed with the clinical researcher in mind, the panel allows clinical researchers to rapidly profile multiple mutations present in cancer samples.